#1FOSUN PHARMA 复星医药 Investor Presentation 2022 Interim Report Prepared in accordance with China Accounting Standards#2Contents 2 3 4 5 Financial Results Strengths Pharmaceutical Med Tech Healthcare Services#3Financial Results#4Financial Results Overview Key Financials (RMB million) 1H21 Segment Revenue 1H22 YoY(%) 11% Revenue 16,952 21,340 25.88 17% 1H21 Net profit attributable to shareholders 2,482 1,547 -37.67* Net profit after one-off gain Net operating cash flow R&D Expenditure R&D Expense 1,570 1,862 18.57* 1,707 1,820 6.66 16.97% YoY 1,954 2,399 22.77 14,327 12,248 1,562 1,818 16.39 72% 14% 19% 1H22 67% ■ Pharmaceutical ■ Med Tech ■ Healthcare Services 66.24% YoY* 42.51% YoY (RMB million) 58.24% YoY 4,043 2,837 1,844 2,918 4 Basic EPS (RMB/Share) 0.97 0.60 -38.14* Pharmaceutical Med Tech 1H21 1H22 Note: the sustainable increase of revenue and net profit after one-off gain was mainly due to the new product launches, Covid-19 products sales and the effective control of sales expense. The decrease of net profit attributable to shareholders and basic EPS was mainly due to the decrease in one-off gain, BNTX share price decreased because of market fluctuations and other factors. The change in fair value of financial assets results a one-off loss over RMB1 billion for the reporting period Healthcare Services#55 Financail Results Overview - By Quarter Revenue 28.70% YoY (RMB million) 39,005 28,585 30,307 2019 2020 Operating Cash Flow 53.07% YoY (RMB million) 5.55% QOQ 10.30% QoQ 10,382 10,958 3,222 3,949 2,580 866 955 1Q22 2Q22 2019 2021 Proft Attributable 29.28% YoY (RMB million) 3,322 3,663 4,735 134.55% QOQ 2019 2020 2021 1Q22 Net Profit after One-off Gain 20.60% YoY 2Q22 (RMB million) 32.45% QoQ 3,277 2,234 2,718 1,085 801 1,061 463 2019 2020 2021 1Q22 2Q22 2020 2021 1Q22 2Q22#6Operating Performance Analysis (RMB million) Expense Structure 2021 1H21 1H22 Gross Margin¹ 48.1% 51.3% 45.8% 11.96% YoY 39.69% YoY Selling and Distribution² 23.3% 24.8% 19.5% 1,754 1,963 1,890 1,353 Administrative 8.2% 8.6% 7.8% 1.38% YoY 434 440 Operating Results 52.25% YoY* Affected by the increased investment I in technology | development for | online operation and | increased expense for offline hospitals in | the pandemic (19) (387) Total I Pharmaceutical Med Tech Healthcare Services R&D 9.8% 9.2% 8.5% ■1H21 ■1H22 Finance 1.2% 1.7% 1.2% Operating Results Margins 1H21 1H22 Total Results Margin 10.3% 9.2% Gross Margin minus 24.8% Selling and Distribution³ 26.5% 26.2% Pharmaceutical 11.0% 13.2% 6 Note: The decrease of Gross Margin in 1H22 was mainly due to:1) the unit price increase of some core products due to the increase in labor costs and raw materials under the pandemic; 2) the lower gross margins on not self-developed Covid-19 products; 3) impact of volume based purchasing Note²: The decrease of Selling and distribution rate was mainly due to:1) continuously strengthen the control of sales expanse; 2) the decreased selling and distribution rate of volume-based purchasing products Note3: Gross Margin minus Selling and Distribution remained consistent Note: segment result increased 52.25% YoY, excluding the impact from equity transfer of Yaneng Bioscience, Med Tech 15.3% 10.9% Healthcare Services -1.1% -13.3%#7Business Highlights - The "4IN" Strategy Fosun Pharma maintained solid revenue and operating performance growth in 1H22 from increased sales volume of products launched in last 3 years, sales in Covid-19 related products and effective control of marketing expenses Improving Product Portfolio INnovation Serplulimab Injection (PD-1) for MSI-H was approved in China; sqNSCLC, EC- SCLC and ESCC indications were accepted by the NMPA. SCLC was granted FDA Orphan-drug Designation Entered into a strategic callaboration with Genuine Biotech to develop and exclusively commercialize Azvudine, the first domestic small molecule anti Covid-19 oral drugs Yi Kai Da was approved for LBCL second-line therapy clinical trials by NMPA in August 2022. The second CAR T cell therapy product FKC889 for MCL is in the clinical stage in China mRNA Covid-19 vaccine sales around 8 million doses in Hong Kong, Macau and Taiwan region in 1H22 Products launched in 1H22: 2 innovative medicine/new indication (Serplulimab MSI- H indication, Rituximab RA indication); 14 innovative medicine/indication approved IND Revenue from products launched in the last three years is over 25% in 1H22 INternationalization Enhancing Global Operating RMB7,592 million revenue from regions outside Chinese Mainland and other countries, accounting for 35.58% of the total revenue. Overseas commercialization team with over 1,400 employees. Entered into the collaboration and license agreement with Amgen for the exclusive right to commercialize OtezlaⓇ and ParsabivⓇ in Chinese Mainland, another collaboration case with reputable MNC Henlius entered into the license agreement with companies including Organon, Eurofarma and Getz Pharma to cover the main biologics market including the U.S., EU and other emerging markets with international partners Sublicensed from MPP to manufacture both drug substance and product and commercialize COVID-19 oral drugs Molnupiravir and Paxlovid in agreed low- and middle-income countries Building the 2nd headquarter in the U.S.; has 5 regional distribution hubs in Africa; the largest distribution hub in French-speaking West Africa, the Côte d'Ivoire distribution hub has been put into operation Accelerating strategic upgrade an internal integration . • INtegration Subdivided Pharma Segment into three divisions: Innovative Medicines Divisions, Established Medicines Manufacturing & Supply Division, and Vaccines Division. Manufacturing integration: Henlius Songjiang Facility Plant (1) received GMP certification, increased commercial production capacity from 24,000L to 48,000L; integrating and constructing specialty formulation production facilities in Changde, Xinyi and Changshou, and APIs facilities in Xuzhou and Chongqing Med Tech: Sisram strengthened global direct sales teams. Direct sales revenue accounts for 64.8% of the total revenue in 1H22, compared to 59.7% in 1H21. Integrating of Medical Diagnosis Segment to improve the R&D and manufacturing capabilities of diagnostic instruments Intelligent Operation Driven by Digital Transformation INtelligentization Upgrading the R&D digital platform INNOX2.0 for collaborative innovation to improve the efficiency of R&D project management and explore Al-driven R&D Providing integrated online and offline healthcare services to become the leader of family active health#8Strengths#9Fosun Pharma - Forward-looking Industry Insights Industrial investment empowers innovation and globalization, quick response to challenges and access to cutting-edge fields and technologies Risk Identification Strategy Implementation Identified the Irrationality of High Profit Generic Drugs Prepared quality consistency evaluation before "4+7" drug procurement; accelerating manufacturing integration to improve the competitiveness Forward-looking Globalization Entered into the global market before domestic competitors via industrial investment as domestic market become increasingly competitive Clinical Value-oriented Innovation Since 2009 Building small molecule innovative drugs, antibody drugs, cell therapy platforms etc. • Innovative Technology Launched the first CAR-T cell therapy product in China, Yi Kai Da. Collaborated with BioNTech on mRNA technology Collaborated with Insilico to enter Al-driven drug discovery and development Biopharmaceuticals Launched China's first biosimilar product Han Li Kang Launched the first mAb product Han Qu You approved in both China and EU Han Si Zhuang was granted Orphan-drug Designation by FDA in treating SCLC Innovative Medical Devices Acquired Alma to enter energy-based aesthetic medical devices business and to establish Wellness Ecosystem Found Intuitive Fosun with Intuitive Surgical as the representative of da Vinci robotic-assisted surgical system in China Quick Response against COVID-19 Quick response against COVID-19 by covering products and services in prevention, test and treatment of COVID-19 Industrial Investment & Quick Response Seize the I Opportunities#1010 Differentiated Innovation - from R&D to Market Rituximab Injection Trastuzumab Injection Serplulimab Injection FCN-338 (BCL-2) • FCN-159 (MEK) • ORIN-1001 In-house R&D Azvudine Avatrombopag Tablets • Opicapone • RT002 • Tenapanor Tablets • SurVaxM FS-1502 • Gene Therapy 马来酸阿伏曲油帕片 Doprelet mRNA Covid-19 Vaccine Axicabtagene Ciloleucel In-license • da Vinci Surgical System BIONTECH Kite INTUITIVE • AGILEAD SURGICAL Co-development Diversified R&D System Oncolytic Virus Individualized Vaccine for Cancer Treatment(AC- NP)/Multispecific Immunonano Therapy(MINP) Lung Cancer Early Diagnosis and treatment (Jedicare) Strengthen middle office capabilities including project approval, clinical, registration, etc. Commercialization team with over 6,900 employees to maximize product value Incubation & Early Stage Investments#11Globalization - Maximize Product Value Revenue from regions outside Chinese Mainland and other countries 1H22 Revenue RMB $7,592 million European subsidiary established in 2017 based on various collaborations, to capture the value of innovative medicines Launched the first domestic biosimilar in EU Covering early stage incubation, BD, preclinical and clinical research and other innovative R&D Global Presence RMB5, 198 million in 1H21 % Total Revenue Europe United States Past Now & future 11 35.58% 30.66% in 1H21 1H22 Main Progress The U.S. • • Collaborated with 5 major wholesalers, 16 GPOs, 21 distributors in the U.S. market. 19 collaboration contracts covered 85% of the IDNS Sisram's North American direct sales revenue was USD69.9 million (+42.2% YoY), 40% of the total revenue Africa Côte d'Ivoire Pharmaceutical distribution hub in West Africa has been put into operation; Kenya . Africa India Acquired the third largest pharma distributor in French-speaking West Africa, Tridem Pharma, in 2017 Integrated public markter team in Guilin Pharma with private market team inTridem Pharma Established 5 regional distribution hubs with about 800 people in the commercialization team Strengthening marketing and local manufacturing capabilities Figure number: GS(2016)1666 Acquired the first FDA approved injectables manufacturer in India, Gland Pharma, in 2017 Focusing on complex injectables and expanding to biologics CDMO Accelerating product registration in China 6,099 overseas employees, 16.7% of the total number of employees distribution hub passed the ICRC on- Completed the first stage of globalization site inspection Accelerating the overseas commercialization of competitive products Entered into the U.S. market by exporting formulations and other businesses. Established the U.S. subsidiary in 2017. Has Hengenix Biotech, Fusion and other platforms in the U.S. Building the 2nd headquarter in the U.S. to improve operation Have direct sales team for generic drugs and medical devices Strengthening BD capability of clinical stage products and commercialization capability of innovative medicines#1212 Trustworthy Partner of MNCs Diversified R&D System Forward-looking Globalization Global network with overseas subsidiaries and VC funds >20yrs domestic industrial experiences with complete clinical registration and commercialization system as well as financial, legal and other capabilities Trustworthy partner with numerous collaborations Quick access to cutting-edge fields and technologies through collaboration Reached dozens of international collaborations with well-known MNCs INTUITIVE SURGICAL Kite A GILEAD Company BIONTECH AMGEN® Entered into a distribution partnership with Intuitive Surgical through subsidiary Chindex Medical, brought da Vinci Surgical System to China Announced to found JV Intuitive Fosun with Intuitive Surgical in September 2016 to further collaborate in technology, manufacturing and services Founded JV Fosun Kite with Kite Pharma in 2017 to build the leading cell therapy platform in China Yi Kai Da is the first CAR-T therapy approved in China. FKC889 for MCL is in the clinical stage in China Collaborated with BioNTech to develop and commercialize mRNA Covid-19 vaccine in China in March 2020 Sales over 30 million doses in Hong Kong, Macau and Taiwan region by the end of June 2022 Entered into the collaboration and license agreement with Amgen for the exclusive right to commercialize OtezlaⓇ and ParsabivⓇ in Chinese Mainland to strengthen non-oncology product pipeline Commercialization capability recognized by MNC, exploring new collaboration in innovative medicines#1313 Quick Response - Product Portfolio Against COVID-19 Covid-19 | Antiviral Treatment Azvudine Entered into a strategic collaboration with Genuine Biotech to develop and exclusively commercialize Azvudine, the first domestic small molecule anti Covid-19 oral drugs Obtained emergency conditional approval from NMPA to treat adult patients suffering moderate Covid-19 on July 25th Included in the Covid-19 prevention and control protocal (9th edition); included in the medical insurance in Gansu, Henan, Hainan and other provinces and cities; priced at RMB 270 for a course of treatment Collaborated with Sinopharm to supply Azvudine in China. Azvudine has been delivered to Henan, Hainan and Xinjiang to fight against the Covid-19 pandemic Sublicensed from MPP Sublicensed from MPP to manufacture drug substance and drug Molnupiravir from MSD and to commercialize in 105 low-and middle-income countries Sublicensed from MPP to manufacture drug substance and drug Nirmatrelvir from Pfizer and to commercialize drug substance and Paxlovid from Pfizer (Nirmatrelvir tablets and Ritonavir tablets) in 95 low-and-middle income countries • Others Entered into a license agreement with Kintor Pharma to commercialize Proxalutamide in India and 28 African countries Product pipeline includes long-acting fusion protein | drugs and bispecific nano-antibodies Covid-19 Diagnostic Test Kit & Biomedlab I COVID-19 nucleic acid test kit Received certifications from NMPA, CE, FDA, EUA, WHO EUL, TGA, etc., suppling to more than 10 countries and regions worldwide Covid-19 Vaccine mRNA Covid-19 Vaccine COVID 19 Antigen Test Kit Received certification from NMPA, CE; completed the German BfArM registration; included in the EU COVID 19 Rapid Antigen Tests Common List; received FDA Emergency Use Authorization Collaborated with BioNTech to develop and market mRNA COVID-19 vaccine in China (including Hong Kong, Macau and Taiwan region) Included in the COVID-19 vaccination programmes in Hong Kong and Macau region in March 2021 and was vaccinated in Taiwan region started in September 2021. Vaccine sales over 30 million doses in Hong Kong, Macau and Taiwan region since launched Vaccination for 5-11 years old was approved in Macau and Taiwan region in April and May 2022; vaccination for 6 months to 4 years old was approved in Taiwan region in August 2022#14• • Environmental, Social and Governance Environmental, Social and Governance (ESG) reflects a company's potential for sustainable growth in aspect of environmental protection, social responsibility and corporate governance ESG becomes an important factor to evaluate company's value while regulators requires more detailed ESG disclosure for listed companies. Fosun Pharma responded actively. In 2021, Fosun Pharma's MSCI ESG rating was improved from BB to BBB In August 2022, the first Fortune China ESG Impact List was announced, with 40 companies on the list. Fosun Pharma topped the list for the remarkable achievements in ESG. • E nvironment Established EHS Committee and EHS Working Group to continuously improve EHS policies and set strategic goals for EHS management Zero external environmental pollution incidents and zero major environmental penalties in 2021 Reduced carbon emissions by 24,146 tons, saved 7,465,000 kWh of electricity and 339,000 m³ of natural gas 14 major member enterprises have ISO14001 environmental management system certification, accounting for 41% of the total number of manufacturing member enterprises Social Continuously addressing unmet clinical needs and improving product accessibility and affordability to reach more patients By the end of 2021, antimalarial drug Artesunate has saved more than 48 million lives worldwide. 175 million children in Africa benefited from the SPAQ-CO Dispersible, effectively reducing the incidence of malaria in children under 5 years of age in Africa Since the outbreak of the COVID-19 pandemic, Fosun Pharma has deployed global resources to develop and provide products in preventing, testing and treating COVID-19, to ensure the supply of test kit, emergency drugs and medical devices, including donated 5,000 bottles of Azvudine to Tibet, donated 40,000 COVID-19 Antigen Test Kits to Wuxi etc. • Gulina Governance Established ESG Committee at the Board level to regularly set ESG objectives and identify corporate risks. Strengthening corporate governance and promoting sustainable development with ESG The Anti-Corruption Supervision Department (ACSD) designed a comprehensive anti-corruption system, upholding the value based on honesty and integrity at the headquarter of Fosun Pharma and within member enterprises through training, audits, etc. Upheld the professional, branded, digital and compliant marketing system control 14#15Pharmaceutical#16Pharma Segment Performance Segment Revenue (RMB million) 12,248 16.97% YoY 14,327 1H21 1H22 Innovative Medicines Segment Results Segment Profit¹ (RMB million) (RMB million) 1,353 39.69% YoY 1,890 1,257 25.14% YoY 1,573 1H21 1H22 1H21 1H22 Pharma 3 Divisions Specialization Established Medicines Manufacturing & Supply Vaccine Note1: Segment profit excludes fair value changes of BNTX shares and gain on sale of certain shares 16#17Pharma Segment Core Therapeutic Area Revenue 1H22 Core Therapeutic Area Revenue Cardiovasc ular system Central nervous system 4% 11% API and Intermediates 7% Metabolis m and alimentary system 14% Anti-tumor and immune modulation (RMB million) 49.56% YoY 36.63% YoY 3,629 2,550 2,656 1,705 -2.54% YoY 7.46% YoY 1,419 1,383 1,019 1,095 -31.49% YoY 616 422 Anti- infection 38% 26% Anti-tumor and immune modulation Anti-infection Metabolism and alimentary system Cardiovascular system Central nervous system 1H21 1H22 17 • •. • • Anti-tumor and immune modulation core products: increase was mainly due to the revenue increase from Han Qu You (Trastuzumab Injection), Han Li Kang (Rituximab Injection), and Su Ke Xin (Avatrombopagmaleate Tablets) and the revenue from new launches including Han Si Zhuang (Serplulimab Injection) and Akynzeo (Netupitant-Palonosetron) Anti-infection core products: increase was mainly due to the sales contribution from mRNA COVID-19 vaccine and the sales revenue increase of anti-malarial products (Artesunate) Metabolism and alimentary system core products: decrease was mainly due to the decrease in sales volume and unit price of Atomolan (glutathione for injection) and Fan Ke Jia (thioctic acid injection) after the volume-based purchasing Cardiovascular system core products: increase was mainly due to the revenue increase from heparin series preparations Central nervous system core products: decrease was mainly due to the sales decline of Ao De Jin (Deproteinized Calf Blood Injection) Note: 1H21 revenue is restated by including new core product Wan Su Jing (Engeletin Tablets) and excluding Shi Li Da (amlodipine besylate tablets) from disposed Huanghe Pharma in 1H22#18Pharma Segment Revenue Structure Optimization Ao De Jin You Di Er You Li Tong Bang Ting Yan Hu Ning Past Revenue Structure Changed as Product Portfolio Optimization Now Revenue mainly contributed by: • • • mRNA COVID-19 vaccine: help to against COVID-19 in Hong Kong, Macau and Taiwan Han Li Kang (Rituximab Injection): the first biosimilar product approved in China Han Qu You (Transtuzumab Injection): the first mAb product approved in both China and the EU Su Ke Xin (Avatrombopag Tablets): the first oral drug approved to treat low blood platelet count in adults with long-lasting (chronic) liver disease (CLD) Artesunate and other anti-malarial product: have saved more than 48 million lives 苏可收 HERER LEMS Henlius 注射用曲憲珠单抗 马来酸阿伐曲泊帕片 Doptelet Artesun M 18 匹伐他汀钙片 【非布司他片: Future • Examples of core innovative product pipeline Received NMPA approval for the first innovative biological drug Serplulimab MSI-H indication. The NDA for sqNSCLC, ES-SCLC and ESCC was accepted by NMPA ° Yi Kai Da (Axicabtagene Ciloleucel Injection) became the first CAR-T cell therapy product approved for launch in China in June 2021 long-lasting DaxibotulinumtoxinA product RT002, Bcl-2 inhibitor, ORIN1001, MEK1/2 inhibitor, FCN-159.#1919 Pharma Segment Growth Driver Growth Driver % of 1H22 revenue from products launched in the last three years over 25% Han Qu You (Trastuzumab injection) 1H22 Sales RMB813 million +150.15% YoY Hentus 主財無魚石康卓 Increased 24,000L commercial production capacity Su Ke Xin (Avatrombopag Tablets) 1H22 Sales MB360 million RMB $46 马来酸阿伐曲泊帕片 Doptelet Han Si Zhuang (Serplulimab Injection) Launched for 3 months 新魯利单抗注射液 Sales RMB 77 million Completed tenders on procurement platforms in 18 provinces Treated 2,485 patients Han Li Kang (Rituximab Injection) 1H22 Sales RMB819 million RA indication was approved in February 2022 MEROR mRNA COVID-19 vaccine 1H22 sales in Hong Kong, Macau and Taiwan region over million doses 최초 8 復必藥 YOONATY Approved to use in children aged 5 to 11 in April/May in Macau/Taiwan region#2020 Innovative R&D - Expenditure & Major R&D Progress • • • 1H22 R&D Expenditure RMB2,399 million 1H22 R&D Expense RMB1,818 million Pharma R&D expenditure is RMB2,062 million, 14.39% of Pharma revenue. Pharma expense is RMB1,491 million, 10.41% of Pharma revenue Strong R&D capabilities with 260 ongoing pipeline projects by the end of 2021 (not including Gland Pharma's pipeline) Major R&D progress R&D Expenditure & Expense (RMB million) 22.77% YoY 1,954 16.39% YoY 2,399 1,562 1,818 R&D Expenditure R&D Expense 1H21 ■1H22 Pharma R&D Expenditure & Expense % Pharma Revenue 16.04% YoY 1,777 2,062 %Pharma Revenue 14.39% Pharma R&D Expenditure 10.41% 7.65% YoY 1,385 1.491 Pharma R&D Expense Serplulimab injection (PD-1) :1) MSI-H was approved by NMPA in March 2022; 2) the NDA of PD-1 in combination with chemotherapy in treating sqNSCLC was accepted by NMPA in September 2021; 3) the NDA of PD-1 in combination with chemotherapy in treating ES-SCLC was accepted by NMPA and SCLC was granted FDA Orphan-drug Designation in April 2022; 4) the NDA of PD-1 in combination with chemotherapy in treating ECSS was accepted by NMPA in August 2022 FS-1502 (Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection Monomethyl Auristatin F): initiated Phase 2 clinical trial in Chinese Mainland in treating NSCLC; 2) approved to enter Phase 2 clinical trial in combination with Serplulimab and/or chemotherapy in treating advanced gastric cancer with HER2 expression in Chinese Mainland FCN-159 (MEK1/2 inhibitor): 1) approved to enter Phase 2 clinical trial in Chinese Mainland in treating histiocytic tumor and arteriovenous malformation;2) ongoing Phase 2 global multi-center clinical trial in treating Neurofibromatosis type 1 Progress in 1H22: launched 2 innovative medicine/new indication (Serplulimab MSI-H indication, Rituximab RA indication); launched in total 10 generic drug/indication in Chinese Mainland and the U.S.; 1 innovative medicine/indication and 18 generic drug/indication NDA in Chinese Mainland; 14 innovative medicine/indication and 9 generic drug/indication IND in Chinese Mainland#2121 * Innovative R&D - In-house R&D Enhance in-house R&D capabilities Henlius 2 Henlius Pipeline covers oncology, autoimmune areas etc.; launched China's first biosimilar product Han Li Kang, and the first mAb product Han Qu You approved in both China and EU Fochon FOCHON PHARMACEUTICALS Pipeline candidates FCN-437 in Phase 3 clinical trial; FCN-159 (MEK1/2) clinical trial in China, U.S. and Europe; the right outside of Chinese Mainland, Hong Kong and Macau of FCN-338 (BCL-2) was granted to Lilly ①⑦ 复星弘创 Novelstar Novelstar FOSUN ORINOVE Fosun Orinnove First-in-Class R&D strategy. Pipeline candidate Orin1001 is with novel target, MOA and compound A FOSUN PHARMA Company R&D of special formulation for multiple DDSS including transdermal, inhalation, slow- release and controlled-release DOU Gene Therapy Platform siRNA Therapy Platform Figure number: GS(2016)1666 XXX Nanobody and Bispecific Antibody Platform Oncolytic Virus Platform Personalized Therapeutic Tumor Vaccine (AC-NP) & Multi-specific Immuno-nano Therapy (MINP) mRNA Platform Cell Therapy Platform Fusion Protein Platform#22Innovative R&D - License- In & Out Maximize product value AkynzeoⓇ License In Granted with exclusive right to Cases I commercialize Akynzeo®, AloxiⓇ i and Anamorelin in Chinese Mainland, Hong Kong region and Macau region #HELSINN Furmonertinib Granted with exclusive right to commercialize furmonertinib in broad region •艾力斯 I OtezlaⓇ & ParsabivⓇ ¦¦ Granted with exclusive right to I commercialize 2 innovative ! medicines, OtezlaⓇ and ParsabivⓇ, in Chinese Mainland AMGEN Azvudine Entered into the strategic collaboration with GENUINE regarding Azvudine, the first domestic oral small molecule drug for COVID-19 treatment GENUINE approved in China 热烈 Maximize Product Value 2020/10 2021/10 2022/5 2022/6 2022/7 i BCL-2 inhibitor FCN-338 License Out Granted Lilly to develop, Cases manufacture and commercialize BCL-2 inhibitor FCN-338 in regions ! except Chinese Mainland, Hong Kong and Macau in October 2020; Lily shall pay up to USD440 millionnely ה Rituximab, Trastuzumab and Bevacizumab Granted Eurofarma to develop, ! manufacture and commercialize Rituximab, Trastuzumab and Bevacizumab in 16 Latin American countries; Eurofarma shall pay up to USD50.5 million eurofarma 22 your life moves ours ה ון T Pertuzumab & Denosumab I Granted Organon exclusive right to commercialize I Pertuzumab and Denosumab in ex-China countries and regions. Organon shall pay up to USD541 million ORGANON I I#23Innovative R&D - Co-development Co-development cases: Deepen international collaboration, accessing cutting edge technologies Yi Kai Da (Axicabtagene Ciloleucel Injection) became the first CAR-T cell therapy product approved for launch in China in June 2021 Indication Expansion Significant needs i potential as moving from third-line treatment to second-line treatment • Commercialization ~ 90,000 new NHL patients in China each year, 10,000 patients with third-line treatment* LBCL third-line therapy: Yi Kai Da became the first CAR-T cell therapy product approved for launch in China in June 2021 Yescarta launched in the U.S. in October 2017 LBCL second-line therapy: Yescarta became the world's first CAR-T cell therapy product approved by FDA for LBCL second- line therapy Yi Kai Da was approved for LBCL second-line therapy clinical trials by NMPA in August 2022 Yescarta (ZUMA-1): 5yrs OS 42.6%; for CR patients, 5yrs OS 64.4% Multicenter Clinical Trial in China for Bridging Study: ORR 79.2% Yescarta (ZUMA-7): Yescarta vs. SOC in second-line therapy of r/r DLBCL (Median follow-up: 24.9mths) ORR: 83% vs. 50%; CR: 65% vs. 32% Median EPS: 8.3mths vs. 2mths Established nearly 100 certified treatment centers and 10,000 m² GMP commercial manufacturing facility by the end of July 2022 Exploring diversified payment methods, including commercial insurance and citizen insurance. Yi Kai Da is included in over 50 commercial insurances and 44 citizen insurances by the end of July 2022. Product Pipeline The second indication r/r iNHL was granted Breakthrough Therapy Designation by the NMPA in August 2021 and the clinical trials in China are under process FDA approved Tecartus (brexucabtagene autoleucel) for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL) in July 2020; FKC889 for MCL is in the clinical stage in China Note*: source from Global Cancer Statistics 2018 23 1#2424 Innovative R&D - Incubation & Early Stage Investments Incubation & Early Stage Investments: enrich the R&D pipeline to target cutting-edge technologies at an earlier stage Incubation Early-stage Investment Fosun Lead was founded in 2019, focusing on world- leading biotechnologies and information technologies. Including gene therapy platform GeCell, Al-assisting precision medicine for Oncology, personalized new antigen immunotherapy and others. Other projects includes portable MRI, handheld ultrasound device and Protein Sequencer Fusion is a platform under Fosun Pharma US in Boston and incubated Archimmune Therapeutics which has two immuno-oncology platforms: personalized cancer vaccine (ACNP) and Multi-specific immuno- nano therapy (MINP) Participated in overseas healthcare professional funds such as Pontifax Venture Capital, Berkeley Catalyst Fund I, LP Partners Innovation Fund II, LP for access to leading technologies globally with potential in-license and other collaboration opportunities Fosun Health Capital has completed financing as Fosun's first VC fund for innovative drugs. Project invested so far include Biomissile (bi-specific antibody) and Tianjin JuveStar (medical aesthetic)#25Innovative R&D - Biopharmaceuticals Core Pipeline Therapeu tic Area Product Target/MOA Indication Pre-Clinical IND Phase 1 Phase 2 Phase 3 NDA Anti-tumor HLX101 (Serplulimab) XKGbio +Chemo PD-1 Squamous non-small cell lung cancer 1L Extensive-stage small cell lung cancer 1L Metastatic esophageal squamous-cell carcinoma 1L Limited-stage small cell lung cancer Neo-/adjuvant treatment of gastric cancer Non-squamous non-small cell lung cancer 1L +Bevacizumab PD-1+VEGF Hepatocellular carcinoma 1L +HLX07 PD-1+EGFR Metastatic colorectal cancer 1L Squamous-cell carcinoma of the head and neck 2L Squamous non-small cell lung cancer 1L VEGF Wet age-related macular degeneration +Trastuzumab HER2+HER2 Gastric cancer HLX04-02 ESSEX IZRE HLX22 HLX07 EGFR HLX11 (Pertuzumab) 3 ORGANON HER2 HLX05 (Cetuximab) 4 Bingze EGFR HLX12 (Ramucirumab) VEGFR2 HLX20 PD-L1 Solid tumors (non-small cell lung cancer, esophageal carcinoma, etc.) Breast cancer Metastatic colorectal cancer and squamous-cell carcinoma of the head and neck Gastric cancer, metastatic non-small cell lung cancer and metastatic colorectal cancer Solid tumors Note 1: granted KG Bio to develop and commercialize HLX10 in 10 countries in Southeast Asia Global multi-center clinical trial, NDA accepted by NMPA in September 2021 Granted FDA Orphan-drug Designation in April 2022 Global multi-center clinical trial; First subject had been dosed in Chinese Mainland in May 2022; First subject had been dosed in January 2022 First subject had been dosed in Chinese Mainland Phase 3 clinical trial in November 2021; First subject had been dosed in Latvia Phase 3 clinical trial in April 2022 Initiated Phase 2 clinical trial in Chinese Mainland in September 2021 Approved to enter clinical trials by FDA Initiated Phase 3 clinical trial in Chinese Mainland in April 2022 Phase 1 clinical trial in Australia Note 2: granted ESSEX an exclusive license to develop, manufacture, and commercialize HLX04 in human ophthalmic therapeutic use Note 3: granted Organon exclusive global commercialization rights except for China Note 4: granted Jingze Biotech to commercialize HLX05 in China 25 Note 5: last update on 29th August 2022#2626 Innovative R&D - Biopharmaceuticals Core Pipeline Therapeutic Area FS-1502 Product Indication Target/MOA Non-small cell lung cancer HER2-positive advanced malignant solid tumor HER2 Pre- Clinical IND Phase 1 Phase 2 Phase 3 NDA Approved to enter Phase 2 clinical trial by NMPA in May 2022 FS-1502+Serplulimab HLX14 (Denosumab)1 ORGANON RANKL Anti-tumor HLX26 HLX35² HLX301 HLX13 (Ipilimumab) CTLA-4 HER2+PD-1 LAG-3 BINACEA EGFR×4-1BB HER2-positive locally advanced or metastatic breast cancer Advanced gastric cancer with HER2 expression Approved to enter clinical trials by NMPA in July 2022 Osteoporosis Solid tumors and lymphomas Solid tumors PD-L1×TIGIT Solid tumors Melanoma, renal cell carcinoma and metastatic colorectal cancer Initiated Phase 3 clinical trial in Chinese Mainland in June 2022; approved to enter Phase 3 clinical trial in TGA in July 2022 Approved to enter clinical trials by NMPA in April 2021 Approved to enter clinical trials by NMPA in January 2022; first subject had been dosed in Chinese Mainland in June 2022 First subject had been dosed in Australia in February 2022; Approved to enter clinical trials by NMPA in March 2022; first subject had been dosed in Chinese Mainland in July 2022 HLX15 (Daratumumab) CD38 Multiple myeloma HLX23 CD73 Solid tumors SurvaxM Injection Survivin Malignant glioblastoma Approved to enter clinical trials by NMPA in March 2022 Recombinant Human Blood system Erythropoietin Injection EPO Anemia of renal disease NDA was accepted by NMPA in December 2021 (pre-filled syringe) Recombinant Insulin Glargine INSR Diabetes Injection Metabolism Mixed Protamine Zinc and Digestive Recombinant INSR Diabetes System Insulin Lispro Injection (50R) Liraglutide Injection GLP-1 RT002 Bio 1 Bio 1 Others Diabetes, Obesity Moderate to severe glabellar lines in adults (GL) Completed the enrollment of subjects in Chinese Mainland in September 2021 Cervical dystonia (CD) Completed the enrollment of subjects in Chinese Mainland in January 2022 13-Valent Pneumococcal Vaccine Conjugate Vaccine Prevention of Streptococcus pneumonia Preparing the Phase 3 clinical trial Note 3: last update on 29th August 2022 Note 1: granted Organon exclusive global commercialization rights except for China Note 2: granted Binacea to research, develop, manufacture and commercialize the HLX35 globally except for China (including Hong Kong, Macau and Taiwan region)#2727 Innovative R&D - Small Molecule Core Pipeline Therapeutic Area Project Target/MOA Indication FCN-437c CDK4/6 Breast cancer (1L) Breast cancer (2L) ALK Non-small cell lung cancer SAF-189 ROS1 Non-small cell lung cancer HLX-208 BRAF V600E Solid tumors (metastatic colorectal cancer, non-small cell lung cancer, etc.) LCH and ECD5 Neurofibromatosis type 1 Low-grade glioma FCN-159 MEK Malignant melanoma Pre-Clinical IND Phase 1 Phase 2 Phase 3 NDA Approved to enter Phase 3 clinical trial by NMPA in January 2022; Phase 1 clinical trial in the U.S. Approved to enter Phase 3 clinical trial by NMPA in January 2022; Phase 1 clinical trial in the U.S. Initiated Phase 3 clinical trial in Chinese Mainland in January 2022; approved to enter clinical trials by FDA Approved to enter clinical trials by FDA Approved to enter Phase 1b/Phase 2 clinical trials by NMPA in January 2022 Global multi-center clinical trial Anti-tumor ORIN1001 YP01001 Arteriovenous malformation Histiocytic tumor Solid tumor VEGFR Advanced solid tumor FGFR/PD- L1 Hematological malignancies Relapsed or refractory B-cell lymphoma Advanced malignant solid tumors FCN-3381 Lilly BCL-2 FH-2001 PLK1 Inhibitor PLK1 KRAS mutations in colorectal and non-small cell lung cancer CHK1 Inhibitor CHK1 Ovarian cancer and other solid tumors IRAK4/BTK DLBCL Approved to enter clinical trial by NMPA in May 2022 Approved to enter clinical trial by NMPA in May 2022 Approved Phase 1 clinical trial in the U.S. Approved Phase 1 clinical trial in the U.S.. Approved to enter Phase 1 clinical trial by NMPA in October 2021 Approved to enter Phase 1 clinical trial by NMPA in August 2021 IRAK4/BTK Inhibitor Note 1: granted Lilly exclusive right to develop, manufacture and commercialize in all countries and regions excluding Chinese Mainland, Macau and Hong Kong Note 2: last update on 29th August 2022#28Project Target/MOA Avatrombopag Tablet TPO-R Blood System Tenapanor Tablet NHE 3 Innovative R&D - Small Molecule Core Pipeline Therapeutic Area Indication Chronic idiopathic thrombocytopenic purpura End-stage Renal Disease - Hemodialysis Pre-Clinical IND Phase 1 Phase 2 Phase 3 NDA Ferric Pyrophosphate Citrate Iron replacement for HD patients Metabolism and Digestive Tenapanor Tablet System FCN-342 NHE 3 URAT1 Irritable Bowel Syndrome with Constipation Gout Granted Phase 1 clinical trial by NMPA in November 2021 Molnupiravir RNA polymerase Treatment of COVID-19 Paxlovid 3CL Protease Treatment of COVID-19 Infectious Diseases mRNA vaccine BNT162b2 Immunization to prevent COVID-19 Administrated in Hong Kong, Macau and Taiwan region XDR PA-824 Tuberculosis MDR Tuberculosis Nervous Opicapone Tablet COMT Parkinson's syndromes Launched Pretomanid in the U.S.* Launched Ongentys in Europe* System Fortacin spray Premature ejaculation Launched in Europe* (Lidocaine Prilocaine spray) ET-26 ORIN1001 Others FCN-016 Blood coagulation factor 28 FXLa inhibitor FH2002 Note: last update on 29th August 2022 Anesthesia ROCK Idiopathic pulmonary fibrosis Glaucoma FXLa Antithrombotic Complement Factor B IgA nephropathy and other immune abnormalities Approved to enter Phase 2 clinical trial by NMPA in July 2022 Initiated Phase 1 clinical trial in Chinese Mainland in February 2022; Phase 1 clinical trial in the U.S.#29Manufacturing - Global Manufacturing System (:) Wanbang (t) Yao Pharma Guilin Pharma (Antimalarial drug) Sino API Facility Henlius (+) Gland Avanc Pharma (Special formulation) Chongqing API Facility Small Molecule API O Small Molecule Formulation Biopharmaceutical 29 Henlius +24,000L Commercial production capacity Songjiang Facility Plant (1) received GMP certification, increased commercial production capacity from 24,000L to 48,000L Songjiang Facility Plant (2) is under construction with designed production capacity of 96,000L Global Standard Over 10 production lines for API and formulation of Yao Pharma, Wanbang and Guilin Pharma received GMP certification for the U.S., Europe and other markets The production line of heparin sodium injection of Wanbang passed the on-site review by the FDA and is qualified to supply the U.S. market Gland Pharma received GMP certifications from the U.S., EU, Japan, Australia and other markets Improved Efficiency: from API to formulation Integration of manufacturing facilities to improve efficiency, accelerating the construction of Xuzhou and Chongqing comprehensive facilities and of API facilities in Changsha, Xuzhou and Chongqing ( Sublicensed from MPP to manufacture oral COVID- I 19 drugs from MSD and Pfizer with world-class I manufacturing facilities and to commercialize in agreed low and middle income countries --#3030 Commercialization - Global Commercialization System Pharma Segment Commercialization Team Domestic Team Overseas Team Innovative Products Team BU Based Sales Team & New Retail Team Africa The U.S. and Other Markets Innovative Products Team Focusing on Oncology, immunology and Hepatobiliary; building a sales team with around 2,000 people for innovative medicines including Han Li Kang, Han Qu You, Su Ke Xin, Han Si Zhuang and others Overseas Team African commercialization team with 800 frontline sales personnel has developed digital management, user operation and B2B2C service model to provide a one-stop service support system including registration, circulation, academic promotion, post-launch safety alert and other services and has established a solid foundation for registration, marketing and sublicense from MPP Collaborated with 5 major wholesalers, 16 group purchasing organizations (GPOs), 21 distributors in the U.S. market. Nearly 20 collaboration contracts covered 85% of the integrated network distribution system (IDNs) 1H22 Main Progress Built a team of more than 200 people for Han Si Zhuang and completed tenders on procurement platforms in 18 provinces The largest regional pharmaceutical distribution hub in French-speaking West Africa has been put into operation in Côte d'Ivoire Kenya pharmaceutical distribution hub has passed the International Committee of the Red Cross (ICRC) on-site inspection and has become a qualified supplier of ICRC Entered into the collaboration and license agreement with Amgen for the exclusive right to commercialize 2 innovative medicines, OtezlaⓇ and ParsabivⓇ. in Chinese Mainland. Leveraging Fosun Pharma's commercialization capabilities to reach patient faster Allist granted Fosun Pharma exclusive rights to commercialize Furmonertinib in the broad market (over 1,500 hospitals)#31Med Tech#32Med Tech Segment Performance Segment Revenue (RMB million) Segment Results 66.24%YOY* (RMB million) Segment Profit 52.25%YOY* 42.51% YoY (RMB million) 4,043 2,837 1.38% YoY 434 440 19.97% YOY* 454 53.96% YoY 699 Medical Devices Fosun Diagnosis 32 1H21 Aesthetic Field • 1H22 As the core medical aesthetic platform, Sisram's business covers energy based medical aesthetic devices, injectables, home use devices, aesthetic dentistry 1H21 Respiratory Care • Exploiting home/hospital used respiratory devices market through Breas 1H22 Professional Medical Device | & Consumables 1H21 1H22 Including Da Vinci surgical! robotic system, negative pressure ambulances and other professional medical device ThermoLift Z1 CPAP Skin Tightening Machines Da Vinci Surgical System Negative Portable CT Pressure BodyTomⓇ Ambulance Providing comprehensive solutions including immuno diagnosis, biochemical diagnosis, microbiological diagnosis, molecular diagnosis, POCT, ICL, etc Actively integrating the operation and continuously improving R&D and manufacturing | capabilities of diagnostic instruments COVID-19 RT-PCR Detection Kit F-C800p Automatic Biochemical Analyzer F-i3000 Automated Chemiluminescence Immunoassay Analyzer Note: Revenue from Med Tech increased by 66.24% YoY, segment result increased by 52.25% YoY, segment profit increased by 19.97% YoY, excluding the impact from equity transfer of Yaneng Bioscience COVID-19 Rapid Antigen Test#33Medical Devices - Sisram Medical Establishing global Wellness Ecosystem based on energy-based devices business and extending to injectables, aesthetic dentistry and personal care 1H22 Main Progress • ' 3 New Launches: 1) an Ultrasound-based system Alma Ted TM to prevent hair loss; 2) CBD+Professional Skincare Solution™M which combines the scientific benefits of full-spectrum CBD, shown to visibly reduce redness and calm the appearance of stressed skin; 3) home use device LMNT one Strengthened global direct sales teams and built a new UK direct sales team. Direct sales revenue accounts for 64.8% of the total revenue in 1H22, compared to 59.7% in 1H21 Financial Performance 39.3% YoY (USD million) 7174.5 1H21 1H22 125.3 1H22 New Launches Alma Energy-based Devices The world's leading supplier of energy-based aesthetic medical devices Launched innovative products including Soprano, ThermoLift Harmony, BeautiFill by LipoLife etc LMNT. Personal Care New brand for personal care New brand LMNT for home use devices Launched the first home use device LMNT one Revenue 25.9% YoY 16.4 Alma Ted 20.6 LMNT one Profit CBD CBD+Professional Skincare Solution Injectables Expansion through collaboration The hyaluronic acid moisturizing product Profhilo and the first long lasting DaxibotulinumtoxinA product RT002 are both under clinical trial in Chinese Mainland Invested in new technologies including silk fibroin-sodium hyaluronate products, fat removal product JS-001 etc. copulla FOSHION Aesthetic Dentistry Integrated Fosun resources with the acquisition of Foshion (the dental brand) in July 2021 Building the new global digital dentistry brand, copulla 33 Note: sublicense of RT002 is subject to approval of the Independent Shareholders#3434 Medical Devices - Intuitive Fosun 2017 2019 2020 2021 2022 Future Localization Process Announced to form a JV with Intuitive Surgical in China in 2016 based on the long-term partnership and established Intuitive Fosun in Shanghai in 2017 Marketing the 4th generation Da Vinci XI Surgical System Da Vinci Surgical System test drives in more than 10 cities across China, with more than 800 doctors from nearly 200 hospitals participating in the experience Da Vinci Innovation Center opened with 1,700 m² of space to provide high-quality hands-on precision medicine training to approximately 4,000 doctors per year Building da Vinci Surgical Manufacturing R&D Center in Shanghai, covering about 31.2 acres Localization in technology, manufacturing and services Made in China Joint R&D Global Commercialization • • Main Products Da Vinci Surgical System 24 da Vinci Surgical Systems were installed in China in 1H22. As of June 30th 2022, nearly 300 Systems were installed in Chinese Mainland, Hong Kong and Macau and completed more than 250,000 surgeries As of June 30th 2022, 7,135 systems were installed worldwide, with more than 55,000 doctors trained to use the system, and performed over 10 million surgeries. lon Endoluminal System The robotic-assisted bronchoscopy platform, lon, was approved by FDA in 2019 The lon guided lung nodule biopsy clinical feasibility trial completed enrollment at Shanghai Chest Hospital in October 2021. It is the first clinical trial using lon outside the United States#35Reagent & Services Instrument Medical Diagnosis - Core Product Biochemical Immunodiagnostic F-C800 F-C800p 77 Routine Biochemical Reagents XPT 5MyCare (Spiritual) F-i1000 Molecule + Respiratory Microbiology & Tuberculosis POCT Chronic Diseases POCT Acute Infections Early Tumor Screening SLAN Amplifier Rapid Fluorescence 528 318 Molecule POCT GU-2 MLA F-i3000 TB ES-15 COVID-19 Extractor GULP Rapid Antigen Test Tumor Markers 15, Thyroid Function8, Gastric Function3, Infection3, Carbohydrate Metabolism2, Sexhormone8 12 Routine PCR COVID-19 RT- PCR Detection Kit Universal Extraction Reagent Monkeypox PCR Detection Kit NG-Test Blood Glucose Disk Susceptibility Test for Fungal/Bacteria Uric Acid (Ag) COVID-19 Rapid Antigen Test G-TEST Tuberculosis I-SPOT Blood Lipid • • • 35 Medical Diagnosis 1H22 Major Progress In-House Development Collaboration Services Promoting the integration of medical diagnosis segment to continuously improve the R&D and manufacturing capabilities of diagnostic instruments F-C800p Automatic Biochemical Analyzer launched in June 2022, together with the F-i3000 Automated Chemiluminescence Immunoassay Analyzer, formed Fosun Diagnostics biochemical immunoassay pipeline to meet the clinical diagnostic testing needs Self-developed COVID-19 Rapid Antigen Test was approved by NMPA in April 2022. It has received EU CE certification and FDA EUA, been included in the EU Common list of COVID-19 antigen tests and completed BfArM registration in Germany Self-developed Monkeypox PCR Detection Kit received EU CE certification in May 2022#36Healthcare Service#37Healthcare Service Segment Performance Segment Revenue (RMB million) 38.39%YOY* Segment Results (RMB million) 1,844 58.24% YoY 2,918 -RMB368 million YoY* Segment Profit (RMB million) 1H21 1H21 1H22 1H21 (19) 1H22 (15) (387) Investment 2011-2017 • Built on-site healthcare network Gained experience in high-end healthcare Launched online healthcare services Operation 2018-2020 • -RMB427 million YoY* 1H22 (442) Strategic Upgrade 2021 and beyond Integrating resources to build Internet healthcare ecosystem Created advantageous specialty areas • Online and on-site strategic synergy Consolidating the leading position as non- public healthcare provider • Developed high-end aesthetic medical business • Building intelligent Cloud Healthcare • Constructing specialties for health and wellness • Building healthcare ecosystem Developed regional medical centers Note: the revenue growth was mainly due to the growth of online business and the recovery of revenue from offline hospitals. Segment revenue reached RMB 2,552million, 38.39% YoY, excluding the impact of acquiring Guangzhou Xinshi Hospital Note: the decrease of segment results and segment profit was mainly due to the increased investment in technology development for online business and increased expense for offline hospitals during the pandemic#38Healthcare Services - Offline Services Highlights Covered Region Pearl River Delta, Yangtze River Delta, Beijing-Tianjin-Hebei Area, the Central of China and Sichuan- Chongqing Area 5,732 beds¹ in medical service institutions controlled by the Group by the end of June 2022 Healthcare Resources 3000+ doctors 50+ holding and invested hospitals Collaborated with 220k+ doctors, 20k+ hospitals Competitiveness Foshan Chancheng Hospital received JCI certification and the TOP1 non-public hospital in China for 4 consecutive years² Shenzhen Hengsheng Hospital was granted JVF license Major Hospitals Pearl River Delta Other Strategic Region Regional flagship hospitals include Foshan Chancheng, Shenzhen Hengsheng, etc. 佛凶禪醫 Fashion Fon Chancheng Hospital 佛山是星禅城医院 JCI国际认证医院 Organization Accredited by Joint Commission International Class III General Hospital with 1,200 beds Realized revenue of RMB2,010 million (+22%), and profit of RMB158 million (+16%) in 2021 Fosun Pharma currently holds 86.47% of the share ④ 深圳恒生医院 • SHENZHEN HENGSHENG HOSPITAL Class III General Hospital with 600 beds Acquired 60% stake of Shenzhen Hengsheng Hospital for RMB909 million in November 2017 廣東藥科大学附属第三医院 新 市 医 Bi Class III General Hospital with 800 beds and over 900 doctors and employees Acquired 70% stake of Guangdong Xinshi Hospital in January 2022 SR SUQIAN ZHONGWU HOSPITAL 宿迁市钟吾医院 宿迁市肿瘤医院 SUQIAN CANCER HOSPITAL j 卓尔荟 JOYFUL WAY |安徽济民肿瘤医院 ANHUI JIMIN CANCER HOSPITAL 温州老年病醫院 WENZHOU GERIATRIC HOSPITAL 星荣整形外科医院 SHINRONG PLASTIC SURGERY HOSPITAL 湖北省人民射院武汉济和医院 HUBEI GENERAL HOSPITAL MEDICAL CONJOINED WUHAN JIHE HOSPITAL STAR HOSPITAL | 上海复星医疗旗下高品质医院 星晨タル医保定点医院 38 Note1: Last update in June 2022 Note2: According to Ailibi ranking#39• • Healthcare Services - Online Services Domestic regulatory, including the 14th Five-Year-Plan, supports the service model of online and onsite healthcare services. Fosun Health will continuously accelerate digitalization and provide patient with closed loop services Integrated online and offline healthcare services from 2021, has received 8 internet hospital licenses as for now Building online medical service platform to provide healthcare services, pharmaceutical and med tech e-commerce, health insurance service and health management services. Pharmacy Pharmacy SaaS, Multi-Scenario Healthcare Department SaaS, Post-Visit Management DTP, Shared Prescription General Health Needs Payment Citizen Insurances, Chronic Disease Management User Type Business Model Health Promotion, Preventive Care, Treatment of acute and chronic illness and Rehabilitation S2B2C B2C 020 Third-Party Platforms Oncology | Kidney Diseases | Pediatrics | Chronic Illness | overseas | Intelligent Devices 万邦医药 Specialized 国药控股 Supply Chain 国药集团 SINOPHARM SINOPHARM HOLDING 复星弘创 FOSUN ORINOVE 万邦汉方 2 Henlius 廣貫堂 夏小美。 Eisai ACTIVE* BREAS hipee 俏维俪BB 康尚 Konsung TONG HAN 1783 CHUN TANG GSP + self-operated central warehouse + collaborated distribution 60 cities next-day delivery, the national average is 1-3 days Collaborated with domestic distributor and pharmacy 020 delivery in 300 cities with same-day delivery goal 39#4040 Sinopharm Performance Revenue (RMB million) 4.96% YoY 249,120 261,471 1H21 1H22 Profit Attributable Profit Attributable to Fosun Pharma (RMB million) (RMB million) 3.10% YoY 3,583 3,694 2.80% YoY 890 910 1H21 1H22 1H21 1H22 . Vigorously promoted the operational innovation and technology upgrading of pharmaceutical distribution services, enhance the scalable, professional and tailoring services advantages of pharmaceutical distribution. 1H22 revenue from pharmaceutical distribution was RMB196,523.94 million (+3.19% YoY), successfully resisted the pandemic challenge and maintained a relatively stable development trend. Utilized national leading network service capability and resource allocation advantages of medical device industry to provide all-round distribution services for various governments authorities and corporate customers. 1H22 revenue from device distribution was RMB53,684.24 million (+12.36% YoY), and the growth rate continuously surpassed the growth of the pharmaceutical distribution Made efforts to speed up the acquisition of qualifications and the introduction of varieties, continuously improved the operation efficiency and strengthened the comprehensive service capability for C-end patients and consumers. 1H22 revenue from the retail pharmacy business was RMB15,274.10 million, (+11.31% YoY), and the operating profit margin of retail business (+0.05 percentage point YoY)#4141 • Disclaimer and copyright 本文件中所包含的所有内容(包括预测性描述),复星医药、陈述人或提供人不保证其完全准确、完整或及时,如因有关内容存在错误、遗漏或失 准之处而引致的行为或结果,复星医药、陈述人或提供人对此不承担责任。 本文件内容不包含亦不应被视为任何投资建议,投资者基于本文件中内容做出的投资决策,责任自负。 本文件及其中所包含内容的所有权利包括版权均由复星医药独家所有,其中相关的“FOSUN”和“复星”字样、图案及相关LOGO标识均为复星医 药合法所有的字号、商标和标识。该等资料和内容未经复星医药书面同意,任何第三方不得以包括转载在内的任何方式加以使用。 Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard. The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials. Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like “Fosun” and”复星” are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting. "#42FOSUN PHARMA 复星医药 持续创新乐享健康 复星医药微信公众号 www.fosunpharma.com